Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: May 27, 2016

New Quest Vantage Cancer Panels

Quest Diagnostics expanded its Vantage cancer test menu with three new services: the MYvantage 34-gene Hereditary Comprehensive Cancer Panel, which includes 34 high risk, moderate risk, and emerging risk genes associated with a broad spectrum of hereditary cancers; the Glvantage Hereditary Colorectal Cancer Test, which includes 13 genes predominantly associated with colon and gastric cancers; and the Qvantage Hereditary Women's Health Cancer Test, which includes 14 genes predominantly associated with breast, colon, uterine, and ovarian cancers. Each tests only include genes that meet certain criteria, such as two-fold increased cancer risk, association with a disease syndrome for which cancer may occur, and guideline support for genetic counseling, the company said.

Granger Dx's Wound~Seq

Granger Diagnostics has launched Wound~Seq, a next-generation sequencing test for wounds and infections. The molecular diagnostic test aims to discover all bacteria, all fungi, all parasites, and select viruses present in a wound or infection using a simple swab of area. It's the second next-generation care test in the company's pipeline following Gynecologene, a laboratory test for bacterial vaginosis.

Bio-Rad's Amplichek II Quality Control

Bio-Rad Laboratories has launched the Amplichek II, an independent, multi-analyte quality control test that monitors the performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of healthcare-associated infections. It was recently issued a de novo clearance from the US Food and Drug Administration, and it is the first in a series of infectious disease controls that Bio-Rad plans to introduce to the molecular diagnostic testing market, the company said.

For more new products and services, please visit the New Products page on our website.